Accuracy of subjective and objective handwriting assessment for differentiating Parkinson’s disease from tremulous subjects without evidence of dopaminergic deficits (SWEDDs): an FP-CIT-validated study
- 747 Downloads
Handwriting examinations are commonly performed in the analysis of tremor and Parkinson’s disease (PD). We analyzed the accuracy of subjective and objective assessment of handwriting samples for distinguishing 27 PD cases, 22 with tremulous PD, and five with akinetic-rigid PD, from 39 movement-disorder patients with normal presynaptic dopamine imaging (subjects without evidence of dopamine deficiency or SWEDDs; 31 with dystonic tremor (DT), six indeterminate tremor syndrome, one essential tremor, one vascular parkinsonism). All handwriting analysis was performed blind to clinical details. Subjective classification was made as: (1) micrographia, (2) normal, or (3) macrographia. In addition, a range of objective metrices were measured on standardized handwriting specimens. Subjective assessments found micrographia more frequently in PD than SWEDDs (p = 0.0352) and in akinetic-rigid than tremulous PD (p = 0.0259). Macrographia was predominantly seen in patients with dystonic tremor and not other diagnoses (p = 0.007). Micrographia had a mean sensitivity of 55 % and specificity of 84 % for distinguishing PD from SWEDDs and mean sensitivity of 90 % and specificity of 55 % for distinguishing akinetic-rigid PD from tremulous PD. Macrographia had a sensitivity of 26 % and specificity of 96 % for distinguishing DT from all other diagnoses. The best of the objective metrices increased sensitivity for the distinction of SWEDDs from PD with a reduction in specificity. We conclude that micrographia is more indicative of PD than SWEDDs and more characteristic of akinetic-rigid than tremulous PD. In addition, macrographia strongly suggests a diagnosis of dystonic tremor.
KeywordsParkinson’s disease Macrographia Micrographia Handwriting SWEDDs (subjects without evidence of dopaminergic deficit)
Conflicts of interest
DG has received consultancy fees from Civitas Therapeutics Inc, Vectura Group plc, and honoraria from Teva/Lundbeck, UCB Pharma, GSK, Pharmacia, and Abbott. Nin Bajaj—Stock Ownership in medically-related fields: none; Consultancies: none; Advisory Boards: UCB Pharma, GE Healthcare; Partnerships: none; Honoraria: UCB, Teva, GE Healthcare, Genus; Grants: MRC, Parkinson’s UK; Intellectual Property Rights: none; Expert Testimony: none; Employment: NHS; Contracts: none; Royalties: none. P.G. Bain: none.
- 4.Fahn S (2005) Does levodopa slow or hasten the rate of progression of Parkinson’s disease? J Neurol 252(Suppl 4):VI37–VI42Google Scholar
- 5.Marek K, Jennings D, Seibyl J (2005) Long-term follow-up of patients with scans without evidence of dopaminergic deficit (SWEDD) in the ELLDOPA study. Neurology 64:A274 AbstractGoogle Scholar
- 8.Soane T, Grosset D, Lees A, Bajaj N (2009) Scans without evidence of dopaminergic deficit: diagnosis, etiology, and management. Curr Med Lit 25(4):93–103Google Scholar